What's happening
This bill requires insurance policies in New York to cover testing for familial dysautonomia, Canavan's disease, and Tay-Sachs.
Why it matters
Improves access to early genetic screening. for families at risk of serious, inherited neurological diseases, potentially enabling earlier intervention, informed reproductive decisions, and better disease management.
Applies to both individual and group health insurance policies. , ensuring broad and consistent coverage for these specific genetic tests across most insurance plans in New York.
Protects patient privacy. by allowing proof of testing through a simple laboratory acknowledgment, reducing the risk of sensitive genetic information being mishandled or unnecessarily shared with insurers.
Limits out-of-pocket costs to standard deductibles and co-insurance. , meaning families are less likely to face unexpected expenses for these essential tests, while still aligning with common insurance cost-sharing practices.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Cover Rare Genetic Disease Tests
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to insurance
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Cover Genetic Disease Testing
In Assembly Committee · Insurance · Sponsor Jeffrey Dinowitz
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
2926
2023-2024 Regular Sessions
IN SENATE
January 25, 2023
Introduced by Sen. CLEARE -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance
AN ACT to amend the insurance law, in relation to reimbursement for testing for familial dysautonomia, Canavan's disease and Tay-Sachs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 37 to read as follows:
(37) (A) Every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or reimbursement for diagnostic X-ray services shall provide coverage for testing for familial dysautonomia, Canavan's disease and Tay-Sachs.
(B) Such coverage shall be included at the inception of all new policies and, with respect to all other policies, at any anniversary date of the policy subject to evidence of insurability.
(C) For purposes of this paragraph, in order to maintain the confidentiality of persons tested, receipt of an acknowledgment from the laboratory performing the test for familial dysautonomia, Canavan's disease and Tay-Sachs shall be deemed sufficient evidence of the performance of such testing.
(D) Such coverage may be subject to annual deductibles and co-insurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy.
§ 2. Subsection (l) of section 3221 of the insurance law is amended by adding a new paragraph 21 to read as follows:
(21) (A) A group policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or reimbursement for diagnostic X-ray services shall provide coverage for testing for familial dysautonomia, Canavan's disease and Tay-Sachs.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00847-01-3
(B) Such coverage shall be included at the inception of all new policies and, with respect to all other policies, at any anniversary date of the policy subject to evidence of insurability.
(C) For purposes of this paragraph, in order to maintain the confidentiality of persons tested, receipt of an acknowledgment from the laboratory performing the test for familial dysautonomia, Canavan's disease and Tay-Sachs shall be deemed sufficient evidence of the performance of such testing.
(D) Such coverage may be subject to annual deductibles and co-insurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy.
§ 3. Section 4303 of the insurance law is amended by adding a new subsection (tt) to read as follows:
(tt) (1) A medical expense indemnity corporation, a hospital service corporation or a health service corporation which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or reimbursement for diagnostic X-ray services shall provide coverage for testing for familial dysautonomia, Canavan's disease and Tay-Sachs.
(2) Such coverage shall be included at the inception of all new policies and, with respect to all other policies, at any anniversary date of the policy subject to evidence of insurability.
(3) For purposes of this subsection, in order to maintain the confidentiality of persons tested, receipt of an acknowledgment from the laboratory performing the test for familial dysautonomia, Canavan's disease and Tay-Sachs shall be deemed sufficient evidence of the performance of such testing.
(4) Such coverage may be subject to annual deductibles and co-insurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy.
§ 4. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law, in relation to reimbursement for testing for familial dysautonomia, Canavan's disease and Tay-Sachs
Purpose or general idea of bill
To authorize reimbursement for testing for Familial Dysautonomia, Canavan's disease and Tay-Sachs
Summary of provisions
Amends subsection (1) of Section 3216, subsection (1) of Section 3221 and Section 4303 of the Insurance Law, to authorize reimbursement for Familial Dysautonomia, Canavan's disease and Tay-Sachs testing. The bill also states that in order to maintain the confidentiality of persons tested, receipt of acknowledgment from the testing facility shall be deemed sufficient evidence of testing
Justification
Familial Dysautonomia, Canavan's disease and Tay-Sachs are genetic diseases which cause degeneration of the nervous system, and result in death. No treatment is currently available for any of these diseases, however, an infant can only be afflicted with the disease if both the mother and father are carriers. There is currently a testing system in place which screens individuals before marriage to determine if they are carriers. This legislation would ensure that for medical screening for theseindividuals are able to receive reimbursement diseases through their insurance carrier.
Prior legislative history
2019-20 - A.2846 - Referred to Insurance
2017-18 - A.2667 - Referred to Insurance
2015-16 - A.299 - Referred to Insurance
2013-14 - A.4372-A- Referred to Insurance/S.209-A - Referred to Insur- ance
2011-12 - A.264-Referred to Insurance/S.2880 -Referred to Insurance
2009-10 - A.1134-Referred to Insurance
2007-08 - A4447-Referred to Insurance
2005-06 - A2424-A,Referred to Insurance
2003-04 - A9263 - Referred to Insurance
Fiscal implications
None.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.